Liver Cancer Therapeutics Market to Reach USD 7,382.1 Million by 2027; Rising Cases of Liver Cancer

Author : Vaishnavi Bakshi | Published On : 16 Aug 2021

The global liver cancer therapeutics market size is expected to reach USD 7,382.1 million by 2027, registering a CAGR of 20.2% during the forecast period. The emergence of effective drugs and therapies for the treatment of liver cancer will subsequently spur lucrative opportunities for the market, states Fortune Business Insights, in a report, titled “Liver Cancer Therapeutics Market Size, Share &COVID-19 Impact Analysis, By Therapy Type (Targeted Drug Therapy, Immunotherapy, and Chemotherapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027.” The market size stood at USD 1,730.9 million in 2019.


The coronavirus incident has brought the world to an unprecedented stop. We understand that this health crisis has brought an unwonted effect on businesses across various. However, this too, shall pass. Rising support from governments and several companies can help in the fight against this highly infectious virus. There are some industries that are struggling, and some are thriving. More or less, nearly every sector is estimated to be impacted by this pandemic. We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.


Request Sample PDF




The Liver Cancer Therapeutics   Market report offers an in-depth analysis of the Liver Cancer Therapeutics   industry and the demand drivers by highlighting information on several aspects of the market. Prudent Markets addresses all these aspects and provides the latest scoop and detailed eye-opening study on all major & emerging business segments. In addition to this, the report sheds light on the industry developments by key players, which are contributing to the expansion of this industry. The development scope, feasibility study, Liver Cancer Therapeutics   market concentration, and maturity analysis is elaborated in this report.


Information given in the research report pertains to different technological advancements introduced in recent years, which allows for a meticulous analysis of the industry and offers a more comprehensive understanding to the readers.


The outbreak of covid-19 in the global market has made companies uncertain about their future scenario as the prolonged lock-down finds a serious economic slump. The latest survey on COVID-19 Outbreak-Global Liver Cancer Therapeutics   Market is conducted to provide hidden gems performance analysis. Essential growth factors and study of Basis points [BPS] have been discussed in the following report. Research Report explains a detailed overview of market dynamics, segmentation, product portfolio, business plans, and the latest development in the industry.


The report on the liver cancer therapeutics market, specifically mentions minute and significant improvements in the global market in recent times. The report also offers a wide-ranging study fixated on emerging trends and new innovative products. The robust research methodology involving primary interviews and desk research is covered in the report while also providing a noteworthy overview of the R&D activities and latest developments to support emerging companies to strengthen their position and strategize to remain at the forefront.


Highlights of the Report:

  1. Market Penetration: Comprehensive information on the product portfolios of the top players in the Supply Chain Analytics market.
  2. Product Development/Innovation: Detailed insights on the upcoming technologies, RandD activities, and product launches in the market
  3. Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market
  4. Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies
  5. Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Supply Chain Analytics market


Market Driver:


Rising Cases of Liver Cancer to Boost Market


The increasing incidence of liver cancer is expected to expedite the growth of the market during the forecast period. Alcohol & tobacco consumption, smoking, and environmental factors in developed nations are some of the reasons for the prevalence of cancer. The increasing urbanization is expected to bolster the healthy growth of the market in the forthcoming years. According to the World Cancer Research Fund, in 2018, there were around 840 000 new cases of liver cancer. Moreover, the growing demand for effective drugs is predicted further to boost the market's development in the foreseeable future. However, oncology drugs' adverse side effects will consequently restrict their adoption, which will retard the growth of the market.


Our research methodology is robust and includes data triangulation based on bottom-up and top-down approaches. We validated the approximate market number with the help of primary research. Secondary research was conducted to find out detailed information about mergers and acquisitions, collaborations, joint ventures, and agreements. At the same time, we have derived significant information about the market dynamics associated with growth drivers, trends, and obstacles.


Favorable Guidelines and Recommendations for Cancer Drugs to Aid Market Amid COVID


The pharmaceutical companies are adopting strategies to maintain the balance between supply and demand. Health organizations have issued necessary guidelines and recommendations for managing hepatocellular carcinoma patients in the time coronavirus. For instance, the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), National Institute of Health and Care Excellence (NICE) have proposed guidelines. Furthermore, several research studies have confirmed that patients with HCC are at higher risk of contracting the infection. Therefore, these patients were considered in the emergency category during the pandemic. Besides, the increased sales of cancer products will foster healthy growth of the market amid COVID-19. The Report offers figurative estimations for upcoming years on the basis of the recent developments and historic data. For gathering information and estimating revenue for all segments, researchers have used top-down and bottom-up approaches. On the basis of data collected from primary and secondary research and trusted data sources the report will help both existing and new aspirants for Liver Cancer Therapeutics   market to figure out and study the market’s needs, market size, and competition.


Regional Analysis:


Presence of Prominent Companies to Incite Growth in North America


The market in North America is expected to expand radically during the forecast period owing to the rising incidence of liver cancer in the US. The presence of major companies, coupled with the launch of novel products will influence growth in the region. Europe is expected to expand radically during the forecast period due to the R&D investments to develop effective drugs. The higher sales of targeted drug therapy productsis expected to boost the growth of the market in Europe. Asia Pacific is expected to rise excellently during the forecast period owing to the growing number of clinical studies pertaining to liver cancer. The increasing geriatric population is likely to contribute impetus in the region. Latin America, and Middle East & Africa are likely to experience a slower growth rate owing to lower adoption of high-cost liver cancer drugs. Similarly, the lack of product approvals in the majority of the under-developed countries can further dampen the growth of the market in those regions.




Key questions answered in the report:

  1. What will the market growth rate of Liver Cancer Therapeutics   Market in 2026?
  2. What are the key factors driving the global Liver Cancer Therapeutics   Market?
  3. Who are the key manufacturers in Liver Cancer Therapeutics   Market space?
  4. What are the market opportunities, market risk and market overview of the Liver Cancer Therapeutics   Global market?
  5. What are sales, revenue, and price analysis of top manufacturers of Liver Cancer Therapeutics   Global market?
  6. What are sales, revenue, and price analysis by types and applications of Liver Cancer Therapeutics   Market?
  7. What are sales, revenue, and price analysis by regions of Liver Cancer Therapeutics   Market?

Key Development:


November 2020: Exelixis, a genomics-based drug discovery company, located in Alameda, California, announced the approval of CABOMETYX in Japan for the treatment of unresectable hepatocellular carcinoma.


Major companies in the Global Liver Cancer Therapeutics   Market are increasingly focusing on research and development activities to create new and innovative products to stay ahead of the competition. Staying on top of market trends & drivers is crucial for decision-makers to hold this emerging opportunity. The study provides information on market trends and development, drivers, capacities, technologies, and the changing investment structure of the Liver Cancer Therapeutics  Industry.


The Report Lists the Key Companies in the Liver Cancer Therapeutics Market:


  • Bayer HealthCare Pharmaceuticals Inc. (Leverkusen, Germany)
  • Bristol-Myers & Squibb Company (New York, U.S)
  • Pfizer Inc. (New York, U.S)
  • Exelixis, Inc. (California, U.S)
  • Merck Sharp &Dohme Corp. (New jersey, U.S)
  • Eisai Inc. (Tokyo, Japan)
  • Eli Lilly and Company (Indiana, U.S)
  • F. Hoffmann-La Roche Ltd (Basel, Switzerland)
  • Other Players


Enquire before buying: